Completed PHASE4 INTERVENTIONAL 1-arm NCT01399450

Paliperidone ER(Invega®) on Depressive Symptoms of Schizophrenia Patients

Effectiveness of Paliperidone ER(Invega®) on Depressive Symptoms of Schizophrenia Patients: A 8-week Open-label Prospective, Non-comparative Study

Sponsor: Johnson & Johnson

Conditions Schizophrenia

Interventions paliperidone

Updated 8 times since 2017 Last updated: Apr 7, 2019 Started: Aug 31, 2011 Primary completion: Jul 31, 2016 Completion: Nov 30, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Schizophrenia, this trial is completed. The trial is conducted by Johnson & Johnson and has accumulated 8 data snapshots since 2011. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
May 2019 — Jan 2021 [monthly]

Completed PHASE4

Status: Unknown Status → Completed

▶ Show 3 earlier versions

Jun 2018 — May 2019 [monthly]

Unknown Status PHASE4
Feb 2018 — Jun 2018 [monthly]

Unknown Status PHASE4

Status: Recruiting → Unknown Status
Jan 2017 — Feb 2018 [monthly]

Recruiting PHASE4

First recorded

Aug 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Johnson & Johnson
Seoul National University Hospital

Data source: Seoul National University Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Goyang-si, South Korea
• Seoul, South Korea